Description
PTEN Monoclonal Antibody | E-AB-22234 | Gentaur US, UK & Europe Disrtribition
Reactivity: Human
Host: Mouse
Isotype: IgG
Application: IHC-p
Research Area: Cancer, Cell Biology, Epigenetics and Nuclear Signaling, Metabolism, Signal Transduction
Background: Tumor suppressor. Acts as a dual-specificity protein phosphatase, dephosphorylating tyrosine-, serine- and threonine-phosphorylated proteins. Also acts as a lipid phosphatase, removing the phosphate in the D3 position of the inositol ring from phosphatidylinositol 3, 4, 5-trisphosphate, phosphatidylinositol 3, 4-diphosphate, phosphatidylinositol 3-phosphate and inositol 1, 3, 4, 5-tetrakisphosphate with order of substrate preference in vitro PtdIns(3, 4, 5)P3 > PtdIns(3, 4)P2 > PtdIns3P > Ins(1, 3, 4, 5)P4. The lipid phosphatase activity is critical for its tumor suppressor function. Antagonizes the PI3K-AKT/PKB signaling pathway by dephosphorylating phosphoinositides and thereby modulating cell cycle progression and cell survival. The unphosphorylated form cooperates with AIP1 to suppress AKT1 activation. Dephosphorylates tyrosine-phosphorylated focal adhesion kinase and inhibits cell migration and integrin-mediated cell spreading and focal adhesion formation. Plays a role as a key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. May be a negative regulator of insulin signaling and glucose metabolism in adipose tissue.
Lead Time: 7~10 days
Concentration: 1 mg/mL
Storage: Store at -20°C. Avoid freeze / thaw cycles.
Immunogen: Synthetic Peptide of PTEN
Buffer: PBS with 0.02% sodium azide, 0.5% BSA and 50% glycerol, pH7.4
Purification: Protein A purification
Dilution: IHC 1:100-200
Conjugation: Unconjugated
Calculated Molecular Weight: N/A
Observed Molecular Weight: N/A
Clonality: Monoclonal
